A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with -thalassemia
نویسندگان
چکیده
Maria Domenica Cappellini, Alan Cohen, Antonio Piga, Mohamed Bejaoui, Silverio Perrotta, Leyla Agaoglu, Yesim Aydinok, Antonis Kattamis, Yurdanur Kilinc, John Porter, Marcello Capra, Renzo Galanello, Slaheddine Fattoum, Guillermo Drelichman, Carmelo Magnano, Monica Verissimo, Miranda Athanassiou-Metaxa, Patricia Giardina, Alexandra Kourakli-Symeonidis, Gritta Janka-Schaub, Thomas Coates, Christiane Vermylen, Nancy Olivieri, Isabelle Thuret, Herbert Opitz, Catherine Ressayre-Djaffer, Peter Marks, and Daniele Alberti
منابع مشابه
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Deferasirox (ICL670) is a once-daily oral iron chelator developed for the treatment of chronic iron overload from blood transfusions. A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with beta-thalassemia aged 2 years or older. Patients were randomized and received treatment with deferasirox (n = 296) or deferoxamine (n = 290)...
متن کاملRandomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
BACKGROUND AND OBJECTIVES Iron accumulation is an inevitable consequence of chronic blood transfusions and results in serious complications in the absence of chelation treatment to remove excess iron. Deferoxamine (Desferal, DFO) reduces morbidity and mortality although the administration schedule of slow, parenteral infusions several days each week limits compliance and negatively affects long...
متن کاملExjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
Although blood transfusions are important for patients with anemia, chronic transfusions inevitably lead to iron overload as humans cannot actively remove excess iron. The cumulative effects of iron overload lead to significant morbidity and mortality, if untreated. Although the current reference standard iron chelator deferoxamine has been used clinically for over four decades, its effectivene...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with -thalassemia
Maria Domenica Cappellini, Alan Cohen, Antonio Piga, Mohamed Bejaoui, Silverio Perrotta, Leyla Agaoglu, Yesim Aydinok, Antonis Kattamis, Yurdanur Kilinc, John Porter, Marcello Capra, Renzo Galanello, Slaheddine Fattoum, Guillermo Drelichman, Carmelo Magnano, Monica Verissimo, Miranda Athanassiou-Metaxa, Patricia Giardina, Alexandra Kourakli-Symeonidis, Gritta Janka-Schaub, Thomas Coates, Christ...
متن کاملEfficacy and Safety of Deferasirox for Reducing Total Body and Cardiac Iron in Thalassemia RASHID MERCHANT, JAVED AHMED, *PRADEEP KRISHNAN AND *BHAVIN JANKHARIA
utilized iron chelator produced a dramatic effect on survival of patients with thalassemia. However, DFO has poor oral bioavailability and a short half life, necessitating 12 hours of subcutaneous infusion, rendering therapy extremely cumbersome [1]. Deferiprone (DFP), an orally effective iron chelator, reduces total body iron load and is also effective in removing cardiac iron [1-3]. However, ...
متن کامل